Pharmacologically, sodium-glucose cotransporter 2 (SGLT2) inhibitors, particularly empagliflozin, have shown potential for renal protection by targeting inflammation, mitochondrial dysfunction, and oxidative stress—key factors in cardiac surgery-associated AKI. Here, SLC5A2 is linked to acute kidney injury.